Yiqi said that the second medical investment future leader forum and excellent medical investment camp were successfully held in Hangzhou Bay, Ningbo!

On August 17-18, 2019, the second medical investment future leader forum and excellent medical investment camp was successfully held in Hangzhou Bay, Ningbo Nearly 200 entrepreneurs from the pharmaceutical and medical industry who invested in big coffee, biological medicine and in vitro diagnosis participated in the meeting Although the two days are short, the sparks of dry goods and site collision are really wonderful Let's review them together! At the beginning of the conference, Deng Yatian, deputy general manager of e-trade medical, gave a speech Mr Deng expressed his heartfelt thanks to the strategic partner Hangzhou Bay life science and Technology Park and the mentors who carefully planned and prepared the contents of the conference As a strategic partner of this conference, Zhang Hui, deputy director of Ningbo Hangzhou Bay New Area Investment Cooperation Bureau, made a detailed introduction to the investment environment of life and health industry in Ningbo Hangzhou Bay New Area, showing the investment advantages of the park in terms of location, transportation and industrial basis On the morning of August 17, "investment", "management" and "withdrawal" of preeminent medical investment camp, the host, Ni Binhui, the managing partner of Yueyin fund, made a keynote speech on "search, screening & Evaluation of innovative projects" According to Ni Binhui, "the standards of successful projects in all walks of life are different", generic drugs and innovative drugs have different screening and evaluation methods, and common problems in project evaluation are discussed Yu Jing, general manager of Shanghai Fosun Pharmaceutical investment and general manager of the board of directors, made a keynote speech on "investment practice: due diligence and project negotiation" Yu Jing shared in detail from human resources, profitability, Department interview, business process, finance, audit, investment possibility, etc In response to the above dialects, and how to avoid the pitfalls encountered in the investment, Ni Binhui and Yu Jing answered the sharp questions one by one Yu Guoliang, CEO of Guanke Meibo, served as the host of the meeting on the afternoon of the 17th, focusing on the topics of medical investment management and withdrawal Yu Guoliang made a speech on the theme of "biotechnology investment and management", analyzed the whole process of post investment management, compared the advantages and disadvantages of various management modes, and finally shared the experience of how to form a perfect closed-loop before and after investment based on his own entrepreneurial experience Wang Shuguang, general manager of China International Finance Co., Ltd., made a keynote speech on "new opportunities for IPO: Interpretation of science and technology innovation board and listing of Hong Kong Stock Exchange" First of all, it introduces the listing of medical and pharmaceutical enterprises in the overseas capital market, and interprets the latest trends of scientific and Technological Innovation Board of medical and pharmaceutical industry and Hong Kong stock exchange, and finally focuses on the selection of the listing place In addition, the meeting also carefully set up a student sharing link Mr Lou Guoqiang of Hangzhou Bay life science and Technology Park shared the entrepreneurial model of biotech start-ups and how to improve the success rate of entrepreneurship Based on the problems encountered in the process of post investment service and management, Liu Xi, the investment team of Dachen Caizhi Medical & Biotechnology, shared her feelings and thoughts as an investment practitioner with five practical cases Hu Yang, deputy general manager of Guangfa Securities Investment and medical treatment Co., Ltd., shared the case of the trainees On August 18, the analysis and roadshow of Biomedical & in vitro diagnosis industry of excellence medical investment business was hosted by Tao Feng, the founding partner of Boyuan capital, on the morning of August 18, focusing on the development of biomedical market and project roadshow Li Yangyang, director of aikunwei's China management consulting team, made a keynote speech on "China's biopharmaceutical market panorama" Li Yangyang first introduced and compared the global biopharmaceutical market and China's biopharmaceutical market in detail He emphasized that in the future, China's biopharmaceutical research will focus on the antibody field, and the most popular targets are still PD - (L) 1, HER2, VEGF, ce20 and TNF - α, etc the company's The global layout will be more and more Tao Feng, the founding partner of Boyuan capital, made a keynote speech on "the investment strategy of biological medicine of Boyuan capital", looking forward to the new trend of the industry in the future from the development opportunity of China's biological medicine industry, and the new policy and new environment gave birth to a new Chinese Medical innovation ecology; Tao Feng pointed out that China's medical market is experiencing rapid growth, and more and more innovative drugs are entering the commercialization stage Finally, it introduces the investment layout of Boyuan capital in biomedical field and the main investment decision points of biomedical enterprises Wang Yanbin, deputy general manager of Nanjing beiheng Biotechnology Co., Ltd., made a keynote speech on "universal car-t opportunities and challenges" Zhou Guoqing, chairman of Hongyi Pharmaceutical Technology Co., Ltd., made a keynote speech on "adoptive T cell + oncolytic virus vaccine combined treatment of solid tumor innovative drugs" Wu Chenyan, President of taicangmeinuohengkang Biotechnology Co., Ltd., made a keynote speech on "research and development of universal therapeutic mRNA cancer vaccine" Zhang Shuyong, deputy general manager of Yantai Heyuan aidis Biomedical Technology Co., Ltd., made a keynote speech on "international first new broad-spectrum anti-tumor ADC" Han nianhe, CEO of Shanghai new idea Biomedical Technology Co., Ltd., made a keynote speech on "anti cd-79b antibody drug conjugate" On the afternoon of August 18, tutor Qian Tingzhi, general manager of Jingxu venture capital, served as the host, mainly focusing on the pattern of IVD industry and project roadshow Qian Tingzhi, general manager of Jingxu venture capital, made a keynote speech on "IVD industry pattern and investment opportunities" Firstly, he shared the overall layout of IVD industry with pyramid structure, pointed out that the business of upstream and midstream enterprises gradually extended to downstream, the valuation level exceeded the overall level of medical devices and A shares, and the return trend was obvious Finally, Qian Tingzhi analyzed the first half of IVD investment case of billion yuan Wang Yaqi, co-founder and chairman of Suzhou Ruixun Biotechnology Co., Ltd., made a keynote speech on "progress of domestic digital PCR" Dai Fangping, CEO of Jiangsu Chinese gene, made a keynote speech on "three generation high-throughput sequencing big data artificial intelligence analysis system for cancer" Zheng Liyun, Chinese Academy of Sciences, made a keynote speech on "cross border medical information platform" Pan Weimin, general manager of Jiangsu Meike Medical Technology Co., Ltd., made a keynote speech on "artificial intelligence detection system for gynecological infection" Yang Yidong, founder of Hangzhou Saian Medical Technology Co., Ltd., made a keynote speech on "cancer screening technology platform and clinical application products based on blood ctDNA detection" Qian Mingxin, chairman of Suzhou Tongli biomedical Co., Ltd., made a keynote speech on "Tl-201 / ae01: human anti coagulation factor Xia antibody"